TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06076265

Intervention type: PROCEDURE
Intervention: Radical Gastric Cancer Surgery
Description: Laparoscopic (robotic) radical surgery for gastric cancer
Study: NCT05780918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case-ICU Communication Tool
Description: This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU.
Study: NCT02054260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgicel
Study: NCT06541704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT06672874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation (FPP)
Description: Fermented Papaya Preparation (FPP) is administered in this study as a dietary supplement aimed at assessing its potential benefits for cognitive function and driving performance in older adults. Participants consume FPP as a 3-gram powder dose taken orally three times daily (morning, afternoon, evening) for a total of 8 weeks. FPP is known for its antioxidant and anti-inflammatory properties, which may influence cognitive domains essential for safe driving, such as attention, memory, reaction time, and executive function. This intervention is specifically designed to explore FPP's potential impact on reducing driving errors and improving psychomotor skills in a high-fidelity driving simulation environment.
Study: NCT06671977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMT-Medium Dose
Description: 14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMT-Medium Dose
Description: 14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMT-Low Dose
Description: 10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMT-Low Dose
Description: 10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC-Medium Dose
Description: 0.5 mg over 5 minutes and then 2 mg over and 55 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC-Medium Dose
Description: 0.5 mg over 5 minutes and then 2 mg over and 55 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC-Low Dose
Description: 0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC-Low Dose
Description: 0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
Study: NCT06617325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZP
Description: Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo at prespecified time-points.
Study: NCT04869488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily（Cohort 1、Cohort 4）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
Description: Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Combined With Apatinib
Description: Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
Study: NCT05103514

Intervention type: OTHER
Intervention: Online Survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online Survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online Survey
Description: There are no interventions planned for this study. This is an observational study only.
Study: NCT06608108

Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention
Study: NCT06600321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-BCAT
Description: Administered by intravenous (IV) infusion
Study: NCT06009575

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement Tablets
Description: The intervention group received IST and local culture-based nutrition education

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplement Tablets
Description: The intervention group received IST and local culture-based nutrition education
Study: NCT06224868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: desufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: desufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: desufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
Study: NCT05409118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alto Abdominal Stent Graft System
Description: Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved EVAR AAA Graft Systems
Description: FDA approved comparator of choice
Study: NCT05743725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: 2 gm magnesium infusion for 30 minutes
Study: NCT05935475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical landmark guided dialysis catheter insertion
Description: .: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECG guided dialysis catheter insertion
Description: after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
Study: NCT06600321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-BCAT
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-BCAT
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-BCAT
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by intravenous (IV) infusion
Study: NCT06676241

Intervention type: PROCEDURE
Intervention: endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.

Intervention type: PROCEDURE
Intervention: endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP
Study: NCT06527300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHWD-870 HCl
Description: Administered P.O.
Study: NCT06503679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 1
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 2
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 3
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally
Study: NCT04073706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Description: Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Description: Removal of uterus, tubes and ovaries without retroperitoneal node dissection
Study: NCT04559685

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-Guided Focused Ultrasound device (MRgFUS)
Description: MR-Guided Focused Ultrasound device (MRgFUS) alone
Study: NCT05656742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: oral vitamin D3
Study: NCT05451810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study: NCT06622720

Intervention type: PROCEDURE
Intervention: surgery
Description: The colorectal surgery of any type conducted in any approach in the timeframe

Intervention type: PROCEDURE
Intervention: surgery
Description: The colorectal surgery of any type conducted in any approach in the timeframe
Study: NCT06678841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized elevated cardiac pacing
Description: Personalized elevated cardiac pacing treatment based each patient's height and baseline LVEF.
Study: NCT06675019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
Study: NCT06680037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azercabtagene zapreleucel (azer-cel)
Description: IV infusion
Study: NCT06625775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-10203
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-10203
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-10203
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
Study: NCT06440447

Intervention type: OTHER
Intervention: Adult day program use
Description: Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.

Intervention type: OTHER
Intervention: Other community care (non-attendees)
Description: Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
Study: NCT06336291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 7 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 7 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 10 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 10 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 13 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 13 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 90 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 90 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 90 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 110 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 110 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 110 mg/m2
Study: NCT06683196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: 3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: 3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
Study: NCT06628310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study: NCT06149715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bottle Filter
Description: The household is given a Sawyer Squeeze Water Filtration System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bucket Filter
Description: The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tap Filter
Description: The household is given a Sawyer Tap Water Filtration System.